Compare iShares Russell 2000 ETF (IWM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Summit Therapeutics Inc — how do they compare? iShares Russell 2000 ETF trades at $279 (market cap $77.70B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: iShares Russell 2000 ETF is far larger — about 5.7× Summit Therapeutics Inc's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Summit Therapeutics Inc for 16 Days on average.
| IWM | SMMT | |
|---|---|---|
Market Cap | $77.70B | $13.71B |
Volume | 35,598,983 | 6,173,057 |
52-Week High | $305.06 | $26.38 |
52-Week Low | $229.13 | $12.43 |
Typical Hold Time | 83 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $279.1, up 0.5% on the day. Technical indicators are predominantly bearish, with moving averages and ADX signaling a downtrend, though oscillators like RSI are neutral. The fund lacks traditional valuation ratios as it is an ETF, and recent news highlights its underperformance versus the S&P 500 over the past decade, with concerns about its inclusion of unprofitable companies.
The outlook for IWM is clouded by persistent underperformance and sensitivity to interest rate hikes, which pressure small caps. While offering diversification away from large-cap tech, the fund faces headwinds from economic tightening and narrow market breadth. A rebound hinges on broader market participation and favorable macroeconomic conditions, but near-term risks remain elevated.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
